Skip to content
preclinicalCognitive & Anxiety

Galanin

Also known as: GAL, Galanin-29, Galanin-30

Galanin is a 29-amino-acid (30 in humans) neuropeptide widely distributed in the central and peripheral nervous systems. It modulates pain transmission, mood, cognition, feeding, and neuroendocrine function through three receptor subtypes (GalR1, GalR2, GalR3). Galanin is notable for its role in neuroprotection during seizures — it inhibits excitatory neurotransmission and is being explored as a gene therapy target for epilepsy.

4 cited references·5 researched benefits

Quick Answer

Galanin is a 29–30 amino acid neuropeptide acting through three receptor subtypes (GalR1–GalR3) to modulate pain, mood, feeding, and seizure threshold. It inhibits excitatory neurotransmission, making it a natural anticonvulsant — galanin gene therapy is in preclinical development for drug-resistant epilepsy. It also modulates norepinephrine and serotonin release, linking it to depression and anxiety. Galanin receptor agonists are drug candidates for epilepsy, pain, and mood disorders.

Key Facts

Mechanism
Galanin signals through three Gi/Go-coupled GPCRs: GalR1 (inhibits adenylyl cyclase, opens GIRK channels — anxiolytic, anticonvulsant), GalR2 (activates both Gi and Gq pathways — neurotrophic, pro-survival), and GalR3 (inhibitory — involved in depression). In pain pathways, galanin is upregulated in dorsal root ganglia after nerve injury, where it has biphasic effects: low concentrations inhibit pain (GalR1) while high concentrations may facilitate pain (GalR2). In epilepsy, galanin release during seizures activates GalR1 on glutamatergic hippocampal neurons, hyperpolarizing them and terminating seizure activity.
Research Status
preclinical
Half-Life
~6 minutes
Molecular Formula
C₁₄₅H₂₂₃N₄₅O₄₀S₃
Primary Use
Cognitive & Anxiety
Table of Contents

Benefits

  • Anticonvulsant — inhibits excitatory neurotransmission in the hippocampus, representing a potential gene therapy for drug-resistant epilepsystrong
  • Neuroprotection — galanin protects against excitotoxic neuronal damage in ischemia and status epilepticus modelsmoderate
  • Pain modulation — upregulated after nerve injury; GalR1 agonists show analgesic potential in neuropathic painmoderate
  • Mood regulation — modulates noradrenergic and serotonergic transmission, relevant to depression and anxietymoderate
  • Neurogenesis — GalR2 activation promotes hippocampal neurogenesis and neuronal survivalpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use onlyVariableN/ANot available as a therapeutic. GalR1 agonists and GalR3 antagonists are in preclinical development for epilepsy, pain, and depression. Galanin gene therapy (AAV vectors) is being explored for focal epilepsy.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Cognitive impairment — galanin overexpression can impair learning and memory through cholinergic inhibitioncommon
  • Feeding stimulation — galanin promotes fat-preferring food intake when injected into the hypothalamuscommon
  • Hormonal effects — inhibits insulin secretion and modulates growth hormone releaserare

Frequently Asked Questions

How is galanin being developed for epilepsy treatment?
Galanin gene therapy uses adeno-associated virus (AAV) vectors to deliver the galanin gene directly into seizure-generating brain regions. This produces sustained local galanin expression that inhibits excitatory neurotransmission without systemic side effects. Preclinical studies in multiple seizure models show 50–80% seizure reduction. This approach is particularly promising for drug-resistant focal epilepsy, where traditional anti-seizure medications fail in ~30% of patients.
Does galanin affect Alzheimer's disease?
Galanin-expressing neurons hyperinnervate the basal forebrain cholinergic system in Alzheimer's disease, and elevated galanin inhibits acetylcholine release. This led to the hypothesis that galanin contributes to cognitive decline. However, recent evidence suggests galanin upregulation may actually be neuroprotective — galanin knockout mice develop more severe neurodegeneration. The current view is that galanin acts as a compensatory neuroprotective response, though its cholinergic inhibition may worsen cognitive symptoms.
How does galanin relate to alcohol and substance use?
Galanin modulates alcohol and drug reward pathways. GalR1 and GalR3 activation in the ventral tegmental area influences dopamine release. Genetic variations in the galanin system are associated with alcohol consumption levels in human studies. GalR3 antagonists reduce alcohol self-administration in animal models, making GalR3 a candidate target for alcohol use disorder treatment. The galanin system also interacts with opioid reward pathways.

References

  1. 1
    Galanin receptors: molecular pharmacology and therapeutic potential(2008)PubMed ↗
  2. 2
    Galanin gene therapy for epilepsy: preclinical progress and translational challenges(2015)PubMed ↗
  3. 3
    Galanin and nociception: from basic science to clinical potential(2006)PubMed ↗
  4. 4
    Galanin in the brain: a review of its role in cognition, mood, and neural survival(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19